Latest News

If you are wondering whether Realty Income is still attractively priced at around $57.72, or if the easy money has already been made, this article will walk through how the current price stacks up against its fundamentals. The stock has dipped about 1.3% over the last week but is still up 1.4% over 30 days, 9.7% year to date, and 10.4% over the past year. This quietly hints that the market may be rethinking both its growth prospects and risk profile. Recently, investors have been focused on...

Vistra (VST) is back in the spotlight after a flurry of bullish catalysts, from an S&P Global credit upgrade to new natural gas projects aimed at feeding power hungry data centers and AI growth. See our latest analysis for Vistra. Those catalysts are landing against a choppy backdrop, with the share price at $170.1 after a recent pullback that left the 90 day share price return at negative 18.88 percent. However, the year to date share price return of 13.66 percent and especially the five...

Earlier this week, Exxon Mobil announced that Chief Financial Officer and Senior Vice President Kathryn A. Mikells will retire on February 1, 2026, for health reasons, with long-time insider Neil A. Hansen set to assume both roles on that date. Alongside this leadership change, Exxon Mobil lifted its 2030 earnings and cash flow outlook on the back of technology-driven efficiency gains, higher expected output from advantaged assets like the Permian Basin, and ongoing cost reductions. We’ll...

SCHOTT Pharma KGaA (XTRA:1SXP) has wrapped up FY 2025 with fourth quarter revenue of €247.6 million and basic EPS of €0.22, capping a trailing twelve month stretch that delivered €986.2 million in revenue and €0.97 in EPS. The company has seen quarterly revenue hover between €229.8 million and €256.5 million through FY 2025, with EPS ranging from €0.19 to €0.30, while trailing net income for the period came in at €146.5 million, pointing to solid but slightly thinner margins versus a year...

Recently, BPI Direct BanKo and LLP Exotic Auto Finance each announced new partnerships with ACI Worldwide to overhaul their payment infrastructures, adopting ACI’s issuing, acquiring and Speedpay platforms to support real-time, omnichannel and digital wallet–enabled transactions. These wins highlight how ACI’s modular, cloud-ready payment solutions are being used across very different customer segments, from microfinance in the Philippines to US luxury auto finance, to cut costs, ease...

If you are wondering whether Semtech at around $72.89 is still worth a closer look, or if the big money has already been made, you are in the right place to work out what the current price really implies. The stock has pulled back about 8.4% over the last week, but it is still up 7.8% over 30 days and 17.4% year to date, with a 163.1% gain over 3 years that naturally raises questions about what comes next. Recent moves have been driven by growing investor attention on Semtech's role in...

Earlier this week, Guardant Health and Trial Library announced a collaboration to pair Guardant’s precision oncology diagnostics and real-world genomic data with Trial Library’s AI-powered matching and navigation platform, aiming to improve identification, referral and enrollment of cancer patients into clinical trials across more than 320 clinics and 1,500 providers in the United States. This partnership is distinctive because it connects Guardant’s data from over 1 million tested patients...

Atea (OB:ATEA) just landed a sizeable win in Norway, securing a three year IT infrastructure contract with Tradebroker, plus an optional four year extension, worth about NOK 500 million annually. See our latest analysis for Atea. The deal lands at a time when momentum is already picking up, with a 30 day share price return of 7.3 percent and a five year total shareholder return of 71.9 percent, signalling confidence in Atea’s long term trajectory. If this kind of contract win has your...

Recently released analysis highlighted that Constellation Brands’ rankings for financial strength, growth, valuation and predictability have weakened, with elevated debt levels and uncertain growth now weighing on perceptions of the business. An interesting implication is that the company’s historically important reputation for consistency is under renewed scrutiny, as lower predictability scores raise fresh questions about the reliability of its future revenue and earnings trends. Next,...

Wondering if Affirm Holdings is still worth your attention after its massive run a few years back, or if the story has quietly changed while no one was looking? After a huge 3 year gain of 564.5%, the stock has cooled off recently, slipping 1.1% over the last week, 14.8% over the last month, and sitting at a modest 7.6% gain year to date with a 4.9% loss over the past year. Recent moves have come as investors reassess buy now, pay later players like Affirm in light of shifting consumer...

If you are wondering whether Tilray Brands is finally a smart buy or just another volatile cannabis story, you are not alone. That is exactly what we are going to unpack here. The stock has surged about 65.3% over the past week, even though it is still down year to date and has had a rough 3 year stretch. This shows that sentiment can flip quickly when this name gets attention. Recently, Tilray has been in the spotlight as investors react to shifting expectations around US cannabis policy...

In late September 2025, MoonLake Immunotherapeutics revealed that its only drug candidate, sonelokimab, delivered disappointing Phase 3 results, leading to multiple securities class action lawsuits alleging the company misled investors about the drug’s efficacy and Nanobody advantages. The litigation centers on claims that MoonLake overstated sonelokimab’s superiority versus an existing treatment while allegedly not fully disclosing their similar biological targets and unproven clinical...

Celcuity (CELC) recently presented new Phase 3 VIKTORIA-1 data for gedatolisib to oncologists at the San Antonio Breast Cancer Symposium, showing clearly longer progression free survival versus fulvestrant in advanced HR positive, HER2 negative disease. See our latest analysis for Celcuity. These latest VIKTORIA-1 results land after a remarkable run for Celcuity, with a 30 day share price return of 23.61 percent and a 1 year total shareholder return of 740.65 percent, which some investors may...

The Brink's Company recently announced that its board approved a new share repurchase program authorizing up to US$750 million in buybacks, with the plan set to run through December 31, 2027. This authorization amounts to more than 15% of Brink's current market value, signaling management’s confidence in its cash generation and AMS/DRS-led growth strategy. Next, we’ll examine how Brink’s sizable new buyback authorization could reshape the existing investment narrative around capital...

Regencell Bioscience Holdings (NasdaqCM:RGC) has been under pressure after disclosing a Department of Justice subpoena into trading activity and its operational, financial, and accounting practices, a development that immediately sharpened investors focus on legal and governance risks. See our latest analysis for Regencell Bioscience Holdings. Even with the DOJ overhang, Regencell’s share price return has been explosive this year. A year to date surge and a strong 30 day share price gain...

Entegris (ENTG) is back in focus after recent investor commentary highlighted a puzzling mix of earnings beats, weaker guidance, and ongoing margin pressure tied to its expansion push in a still soft semiconductor demand environment. See our latest analysis for Entegris. The mixed reaction to Entegris’ latest quarter mirrors its share price story, with a recent 1 month share price return of 10.13 percent, a softer year to date share price return of 4.81 percent, and a 1 year total shareholder...

Cadeler (OB:CADLR) just locked in a new unsecured green corporate term loan facility of EUR 60 million, with room to lift it to EUR 80 million. This provides the offshore wind installer with additional financial flexibility. See our latest analysis for Cadeler. The new green loan comes after a tough stretch, with the share price at NOK 46.32 and a year to date share price return of negative 29.17 percent. Even so, the five year total shareholder return of 88.68 percent still signals that the...

Recent Performance Sets the Stage Avista (AVA) has slipped about 7% over the past month but is still up around 6% year to date. This combination naturally raises the question of whether the pullback is offering a reasonable entry point. See our latest analysis for Avista. At a share price of $38.56, Avista’s recent 30 day share price return of negative 7.4 percent sits against a more constructive year to date gain and double digit one year total shareholder return. This suggests momentum has...

United Community Banks (UCB) just doubled down on shareholder returns, with its board signing off on a fresh $100 million stock repurchase program running from January 2026 through the end of that year. See our latest analysis for United Community Banks. That new buyback plan lands after a steady climb in sentiment, with a 7.5% 1 month share price return and a 5 year total shareholder return of 33.32%, suggesting momentum is gradually rebuilding from a muted recent patch. If this kind of...

In December 2025, Vestis Corporation reported fourth-quarter sales of US$712.01 million and a quarterly net loss of US$12.55 million, alongside a full-year net loss of US$40.22 million on sales of US$2,734.84 million, reversing the prior year’s profitability. Alongside these widened losses, Vestis guided for fiscal 2026 revenue to be flat to down 2% versus normalized 2025 levels, underscoring management’s cautious outlook on demand and execution. We’ll now examine how Vestis’s wider losses...

Wondering if Kroger at around $63 a share is still a smart buy or if the easy money has already been made? This breakdown is designed to give you a clear, valuation first answer. The stock is up 0.8% over the last week and 2.0% year to date, but that sits against a modest 3.9% gain over 1 year and much stronger returns of 52.4% over 3 years and 127.7% over 5 years, hinting at a long term uptrend that has cooled recently. Recent headlines have centered on Kroger's ongoing antitrust scrutiny...

RPC (RES) has been grinding through a mixed performance lately, with shares slipping over the past week but climbing about 27% in the past 3 months. This has left investors weighing value against cyclical risk. See our latest analysis for RPC. At around $5.68, RPC’s recent 90 day share price return of 27.07% contrasts with a weaker year to date performance. This suggests short term momentum is rebuilding even as longer term total shareholder returns remain uneven. If RPC’s rebound has you...

If you are wondering whether Genmab is still a smart buy after its big run or if most of the upside is already priced in, this breakdown will help you assess whether the current share price reflects its long term potential. The stock is up 31.6% year to date and 40.1% over the last year, despite only modest moves of 2.5% over 30 days and a slight 0.8% dip in the last week. This suggests sentiment has improved even though the longer 3 and 5 year returns are still negative. Recently, Genmab...

Wondering if Novo Nordisk is a bargain or a bubble at today’s price? You are not alone, and this breakdown will clarify what you are really paying for. After a volatile stretch, the stock is up 4.8% over the last week but roughly flat over 30 days, while still sitting deep in the red year to date at -42.7% and down -52.1% over the past year, despite a 44.5% gain over five years. Those sharp swings have come as investors reassess the long term outlook for its blockbuster diabetes and obesity...